Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up – Time to Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price gapped up before the market opened on Friday . The stock had previously closed at $36.16, but opened at $37.28. Supernus Pharmaceuticals shares last traded at $37.09, with a volume of 42,602 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SUPN. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 0.8 %

The business has a 50-day simple moving average of $35.22 and a 200-day simple moving average of $31.85. The company has a market cap of $2.01 billion, a PE ratio of 33.79 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same quarter in the previous year, the firm earned ($0.29) EPS. The firm’s revenue was up 14.2% compared to the same quarter last year. On average, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insider Activity

In related news, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares of the company’s stock, valued at $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the sale, the director now owns 13,315 shares in the company, valued at $487,595.30. The trade was a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 in the last quarter. Insiders own 9.30% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC boosted its stake in Supernus Pharmaceuticals by 47.6% in the second quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock valued at $141,026,000 after acquiring an additional 1,700,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Supernus Pharmaceuticals by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after buying an additional 309,966 shares during the period. Stephens Investment Management Group LLC lifted its stake in Supernus Pharmaceuticals by 1.8% in the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after acquiring an additional 403,028 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.